中轴型脊柱关节炎常规诊疗中TNF抑制剂减量的2年临床与MRI结局及成功减量的预测因素
52%患者成功减量(仅1%停药),97%维持临床缓解,影像学变化轻微。基线医生总体评分是成功减量的独立预测因素。
要点
- 临床缓解的axSpA患者按指南减量TNFi,2年时52%成功减量,仅1%停药。
- 基线医生总体评分较低是成功减量的独立预测因素。
- 2年随访中97%患者维持临床缓解,MRI/放射学进展轻微。
核心结论
- 按临床指南对临床缓解的axSpA患者进行TNFi减量,2年后52%成功减量,仅1%停药。
- 基线医生总体评分是成功减量的独立预测因素。
- 减量过程中97%患者维持临床缓解,影像学变化轻微。
研究设计与样本
- 78例(72%)基线接受标准剂量,31例(28%)接受减量剂量。
- 减量方案:基线减至标准剂量的2/3,第16周减至1/2,第32周减至1/3,第48周停药。
- 出现临床、BASDAI或MRI flare(预设标准)者停止减量并恢复至前一剂量。
- 采用多变量回归进行预测分析。
主要发现
- 基线接受标准剂量的患者(n=78)中,较低的医生总体评分是成功减量的唯一独立预测因素(OR=0.79 [95%CI: 0.64, 0.93];P=0.003)。
- 全体患者中,较低医生总体评分(OR=0.86 [0.75, 0.98];P=0.017)、较低SPARCC骶髂关节侵蚀评分(OR=0.78 [0.57, 0.98];P=0.029)和当前吸烟(OR=3.28 [1.15, 10.57];P=0.026)是成功减量的独立预测因素。
- 2年时97%患者处于临床缓解,影像学检查显示轻微变化。
关键数值与推荐
- 临床缓解定义:BASDAI<40且医生总体评分<40,且前一年无疾病活动迹象。
- 减量方案:基线减至标准剂量2/3,第16周减至1/2,第32周减至1/3,第48周停药。
- flare后处理:停止减量并恢复至前一剂量。
临床怎么用
- 对临床缓解的axSpA患者可按指南逐步减量TNFi,多数可成功减量且维持缓解。
- 基线医生总体评分较低者更可能成功减量,可作为决策参考。
- 减量过程中需监测flare,出现flare时恢复前一剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In a 2-year follow-up study of patients with axial spondyloarthritis (axSpA) in clinical remission who tapered TNF inhibitor (TNFi) treatment according to a clinical guideline, we aimed to investigate the proportion who successfully tapered/discontinued therapy and baseline predictors thereof. The proportion regaining clinical remission after flare and the progression on MRI/radiography were also assessed. METHODS: One-hundred-and-nine patients (78 [72%]/31 [28%] receiving standard and reduced dose, respectively) in clinical remission (BASDAI < 40, physician global score < 40) and no signs of disease activity the previous year tapered TNFi as follows: to two-thirds of standard dose at baseline, half at week 16, one-third at week 32 and discontinuation at week 48. Patients experiencing clinical, BASDAI or MRI flare (predefined criteria) stopped tapering and escalated to previous dose. Prediction analyses were performed by multivariable regression. RESULTS: One hundred and six patients (97%) completed 2 years' follow-up; 55 patients (52%) had successfully tapered: 23 (22%) receiving two-thirds, 15 (14%) half, 16 (15%) one-third dose and 1 (1%) discontinued. In patients at standard dose at baseline (n = 78), lower physician global score was the only independent predictor of successful tapering (odds ratio [OR] = 0.79 [95% CI: 0.64, 0.93]; P = 0.003). In the entire patient group lower physician global score (OR = 0.86 [0.75, 0.98]; P = 0.017), lower Spondyloarthritis Research Consortium of Canada (SPARCC) Sacroiliac Joint Erosion score (OR = 0.78 [0.57, 0.98]; P = 0.029) and current smoker (OR = 3.28 [1.15, 10.57]; P = 0.026) were independent predictors of successful tapering. At 2 years, 97% of patients were in clinical remission. Minimal changes in imaging findings were observed. CONCLUSION: After 2 years following a clinical guideline, 52% of patients with axSpA in clinical remission had successfully tapered TNFi, only 1% discontinued. Baseline physician global score was an independent predictor of successful tapering.
引用
- Wetterslev M, Georgiadis S, Sørensen IJ, et al. Tapering of TNF inhibitors in axial spondyloarthritis in routine care - 2-year clinical and MRI outcomes and predictors of successful tapering. Rheumatology (Oxford). 2022. PMID: 34636846. doi:10.1093/rheumatology/keab755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。